|
gptkbp:instance_of
|
gptkb:pharmaceuticals
|
|
gptkbp:administered_by
|
oral tablet
|
|
gptkbp:approves
|
gptkb:FDA
|
|
gptkbp:atccode
|
L01 XE05
|
|
gptkbp:bioavailability
|
59% to 100%
|
|
gptkbp:brand
|
Tarceva
|
|
gptkbp:casnumber
|
183321-74-6
|
|
gptkbp:chemical_formula
|
C22 H24 Cl N3 O4 S
|
|
gptkbp:clinical_trial
|
Phase II
Phase III
|
|
gptkbp:contraindication
|
pregnancy
severe hepatic impairment
lactation
|
|
gptkbp:developed_by
|
gptkb:Genentech
|
|
gptkbp:dosage_form
|
150 mg daily
|
|
gptkbp:effective_date
|
gptkb:2004
|
|
gptkbp:excretion
|
feces
|
|
gptkbp:formulation
|
gptkb:tablet
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Erlotinib
|
|
gptkbp:indication
|
advanced cancer
|
|
gptkbp:interacts_with
|
gptkb:CYP3_A4
CYP1 A1
|
|
gptkbp:invention
|
gptkb:2020
|
|
gptkbp:lifespan
|
about 36 hours
|
|
gptkbp:marketed_as
|
gptkb:Australia
gptkb:Canada
gptkb:European_Union
gptkb:Japan
gptkb:United_States
Tarceva
|
|
gptkbp:mechanism_of_action
|
EGFR inhibitor
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:pharmacokinetics
|
highly protein-bound
inhibits cell proliferation
|
|
gptkbp:previous_name
|
yes
|
|
gptkbp:provides_guidance_on
|
ASCO guidelines
NCCN guidelines
|
|
gptkbp:related_products
|
gptkb:Gefitinib
gptkb:Lapatinib
gptkb:Osimertinib
Afatinib
Dacomitinib
|
|
gptkbp:research_focus
|
biomarkers
combination therapy
personalized medicine
resistance mechanisms
|
|
gptkbp:side_effect
|
fatigue
nausea
diarrhea
liver toxicity
rash
thromboembolic events
pulmonary embolism
anorexia
interstitial lung disease
corneal ulceration
|
|
gptkbp:targets
|
gptkb:EGFR
|
|
gptkbp:used_for
|
gptkb:Oncology
gptkb:pancreatic_cancer
|
|
gptkbp:bfsParent
|
gptkb:EGFR
|
|
gptkbp:bfsLayer
|
5
|